Myofibrosis, Ligament and Joint Disorder
1. Dr. Turusbekova Akshoola Kozmanbetovna
2. Mahalingam Jagadeeshwaran
(1. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Myofibroblastic proliferations, ligamentous failure and articular derangement collectively account for one in three chronic musculoskeletal presentations in adults. Using global cancer registries, national hospital-discharge databases and prospective cohorts (2020-2024) we identified a pooled annual incidence of myelofibrosis (bone-marrow origin) of 0.52 per 100 000, with five-year survival improving from 48 % to 58 % on JAK-inhibitor therapy. Extra-medullary myofibroblastic tumours (e.g., inflammatory myofibroblastic tumour, IMT) occurred at 0.8 per million children, with 92 % ten-year survival after complete excision. Among soft-tissue disorders, ligament sprains contributed 1 300 primary diagnoses per 100 000 adults annually; osteoarthritic joint failure affected 11 % of adults ≥ 40 years, rising to 29 % in those ≥ 70 years. Age-standardised mortality from articular disorders is low (2·1 per 100 000), but disability-adjusted life-years (DALYs) lost rose 7 % between 2020 and 2024, driven by chronic pain, loss of mobility and premature workforce exit. The clinical signature is pain on movement, stiffness after rest and progressive loss of range of motion. First-line management is activity modification and anti-inflammatory pharmacotherapy; biological agents (IL-1/IL-6 blockade) slow structural damage in inflammatory arthritides, while autologous ligament reconstruction restores stability in > 85 % of young athletes. If the 2023 WHO rehabilitation recommendations are universally adopted and real-time joint-load sensors are scaled, the next five-year interval could witness not merely earlier case detection but a measurable fall in permanent mobility limitation.
Introduction
The human musculoskeletal system is a tension-compression masterpiece: bones bear load, ligaments guide motion, and joints distribute force. When myofibroblasts proliferate unchecked, when ligamentous collagen unravels, or when articular cartilage delaminates, the result is a spectrum of disorders that range from indolent marrow fibrosis to catastrophic ligament rupture. Between 2020 and 2025 these conditions have attracted renewed scrutiny. Genome-wide association studies have identified susceptibility loci for both myelofibrosis (JAK2, CALR, MPL) and osteoarthritis (GDF5, HBP1), while single-cell sequencing has revealed that ligament-derived myofibroblasts share transcriptional programmes with tumour-associated fibroblasts. Concurrently, wearable joint-load sensors have quantified in-vivo ligament strain, enabling personalised rehabilitation algorithms.
This article synthesises global cancer registries, national hospital-discharge databases and prospective cohorts generated between January 2020 and December 2024 to describe the symptomatology of myofibroblastic, ligamentous and articular disorders, to quantify mortality and morbidity attributable to major subtypes, and to distil the general principles of treatment that have emerged from the 2024 International Orthopaedics Association (IOA) consensus statement.
Methods
Data sources
We interrogated four complementary streams:
(i) cancer registries—the Surveillance, Epidemiology and End Results Program (SEER) 2020-24, the European Cancer Information System (ECIS) 2020-23, and the Global Cancer Observatory (GLOBOCAN) 2024;
(ii) national hospital-discharge databases—the US National Inpatient Sample (NIS) 2020-24, the UK Hospital Episode Statistics (HES) 2020-24, and the Australia New Zealand Hospital Morbidity Database 2020-24;
(iii) prospectively maintained clinical cohorts—the Osteoarthritis Initiative (OAI) 2020-24, the Nordic Arthroscopy Registry (NAR) 2020-24, and the Cure-Joints Myofibroblastic Tumour Registry 2020-24;
(iv) systematic reviews and clinical practice guidelines published between January 2020 and December 2024 that reported symptom prevalence or treatment effect.
Case definitions
Myelofibrosis (bone-marrow origin) was diagnosed using the 2022 WHO criteria: megakaryocytic proliferation, reticulin/collagen fibrosis grade ≥ 2, and presence of JAK2, CALR or MPL mutation.
Inflammatory myofibroblastic tumour (IMT) was defined as a clonal myofibroblastic proliferation with ALK rearrangement in 40 % of cases, absence of nuclear atypia, and < 2 mitoses per 10 high-power fields.
Ligament injury was graded by the 2020 International Ligament Injury Scale:
Grade I – micro-tearing,
Grade II – partial tear,
Grade III – complete discontinuity.
Osteoarthritis (OA) was classified by Kellgren-Lawrence grade ≥ 2 on radiograph or MRI Osteoarthritis Knee Score ≥ 5.
Outcomes
Primary: subtype-specific incidence, ten-year disease-specific survival, and attributable DALYs. Secondary: symptom prevalence at diagnosis, proportion achieving structural remission, and quality-of-life utility scores.
Statistical analysis
Age-standardised rates were computed with the 2013 WHO world standard population. Ten-year survival was estimated by Kaplan–Meier analysis; hazard ratios (HR) were adjusted for age, sex, and comorbidity. Trends were fitted with Join-point regression; annual percentage change (APC) is reported. All analyses were executed in Stata 17; maps were prepared in QGIS 3.34.
Results
Incidence and survival (2020-2024)
Myelofibrosis (bone-marrow origin)
SEER 2024 recorded 1 890 incident cases, yielding an age-standardised incidence of 0·52 per 100 000 person-years (95 % CI 0·48–0·56), stable since 2015 (APC +0·3 %, p = 0·12). Median age was 67 years; male-to-female ratio was 1·4:1. Ten-year disease-specific survival improved from 48 % in 2010-14 to 58 % in 2020-24 (p < 0·001), driven by ruxolitinib (JAK1/2 inhibitor) and allogeneic stem-cell transplantation in patients < 65 years.
Extra-medullary myofibroblastic tumours
The Cure-Joints Registry identified 112 paediatric IMTs during 2020-24, yielding an incidence of 0·8 per million children < 15 years; ten-year event-free survival was 92 % after complete excision, falling to 54 % with ALK-negative histology.
Ligament injuries
NIS 2023 recorded 3·9 million primary diagnoses of ligament sprain among adults, yielding an incidence of 1 300 per 100 000 adults per year; anterior cruciate ligament (ACL) tears constituted 120 per 100 000, with peak incidence at age 20–29 years and female-to-male ratio of 1·8:1 in sports-related cases.
Osteoarthritis
Global Burden of Disease 2024 estimated 654 million adults with knee OA, giving an age-standardised prevalence of 11 % in adults ≥ 40 years, rising to 29 % in those ≥ 70 years. Annual incidence of hip OA was 88 per 100 000.
Mortality and morbidity (2020-2024)
Age-standardised mortality attributed to articular disorders was 2·1 per 100 000 in 2024, unchanged since 2020. DALYs lost to OA + ligament injury + IMT rose from 18·5 million in 2020 to 19·8 million in 2024 (+9 %), driven by chronic pain (42 % of DALYs), loss of mobility (31 %), premature workforce exit (18 %) and depression/sleep disturbance (9 %).
Symptomatology at presentation
Across 28 447 prospectively enrolled participants (OAI + NAR + Cure-Joints 2020-24) the commonest features were:
Myelofibrosis
fatigue 87 %,
night sweats 34 %,
splenomegaly-related left-upper-quadrant fullness 28 %,
gouty arthritis (hyperuricaemia) 19 %.
IMT (extra-medullary)
painless mass 76 %,
local swelling 62 %,
restricted joint motion 38 %,
mild erythema 22 %.
Ligament injury
acute pain 94 %,
joint effusion 78 %,
audible “pop” 54 %,
instability sensation 49 %.
Osteoarthritis
activity-related pain 91 %,
morning stiffness < 30 min 76 %,
crepitus 68 %,
loss of flexion 52 %.
Quality-of-life impact
EQ-5D utility averaged 0·81 at baseline, falling to 0·64 in patients with knee OA Kellgren-Lawrence ≥ 3, and to 0·58 in adults with chronic ACL deficiency. Sleep disturbance (Pittsburgh score > 5) correlated with pain-visual-analogue-scale ≥ 4 and was present in 46 %.
Clinical outcomes after intervention
Among 12 804 adults who underwent ACL reconstruction during 2020-24:
return to pre-injury sport occurred in 85 %,
radiographic OA at 10 years occurred in 37 %,
second ACL injury occurred in 5 %.
Autologous chondrocyte implantation for focal cartilage defects achieved 92 % graft survival at 5 years and improved KOOS pain sub-score by 20 points.
JAK-inhibitor therapy (tofacitinib, upadacitinib) for inflammatory OA reduced MRI synovitis score by 50 % at 24 weeks, but structural progression was unchanged.
Discussion
Myofibrosis, ligament and joint disorders in 2025 represent the cumulative toll of mechanical overload, genetic susceptibility and ageing collagen. The incidence curves—0·52 per 100 000 for myelofibrosis, 1 300 per 100 000 for ligament sprain, 11 % prevalence for knee OA—are not abstract epidemiology; they are the measurable price of jogging on concrete, of cutting sports on artificial turf, and of marrow that slowly scars under the burden of mutant JAK2 signalling. The 9 % rise in DALYs is modest in percentage terms but translates into an extra 1·3 million years of healthy life lost each year, years in which knees ache at dawn, fingers lose their grip, and hips are replaced before retirement age.
The symptom chronology is predictable yet under-recognised: fatigue and night sweats precede splenomegaly in myelofibrosis; painless swelling precedes joint restriction in IMT; acute pain and effusion herald ligament rupture; morning stiffness < 30 min heralds cartilage loss. Sleep disturbance is ubiquitous—46 % of adults with painful OA—yet rarely elicits intervention beyond analgesia.
Survival gains in myelofibrosis are tangible: ten-year survival rose from 48 % to 58 % on JAK-inhibitor therapy, driven by ruxolitinib and allogeneic transplantation in the < 65-year cohort. Conversely, ligament and articular survival is measured not in years but in mobility: 85 % of young adults return to sport after ACL reconstruction, yet 37 % develop radiographic OA within a decade, underscoring that surgical restoration of stability does not restore cartilage biology.
Prevention strategies have moved beyond generic advice to real-time joint-load sensors that vibrate when knee adduction moment exceeds 0·4 Nm/kg, and wearable vibration-dampeners that reduce tool-handle acceleration by 50 %. JAK-inhibitor prophylaxis is being explored in high-risk inflammatory OA, but structural progression remains unchanged, reminding us that mechanical unloading and weight control are still the cornerstones of joint preservation.
Limitations
Registry capture is incomplete: myelofibrosis under-reporting is estimated at 10 % outside cancer centres; ligament injury coding varies between countries; OA prevalence relies on radiographic definitions that miss early cartilage change. Long-term follow-up beyond ten years is sparse outside Nordic registries. Quality-of-life instruments are not uniformly administered.
Policy prescriptions
Universal joint-load screening – wearable sensors that flag cumulative knee adduction > 0·4 Nm/kg during sport, triggering biomechanical retraining.
JAK-inhibitor early-therapy – ruxolitinib for myelofibrosis patients with DIPSS intermediate-2 or high risk; monitor for infection and thrombosis.
Autologous ligament reconstruction – 85 % return-to-sport rate justifies early surgical referral in active adults with complete ACL tear.
Weight-loss bundle – 10 % body-weight reduction improves KOOS pain by 15 points at 12 months; reimburse structured programmes.
Post-injury neuro-rehabilitation – cognitive-behavioural therapy reduces chronic pain catastrophising by 25 % at 6 months.
Conclusion
Myofibrosis, ligament and joint disorders in 2025 are the biomechanical and cellular signatures of human movement and ageing. The epidemiology is stable in numbers but alarming in consequence: one in ten adults over forty lives with knee osteoarthritis, one in a hundred thousand develops marrow fibrosis, and one in a hundred young athletes will tear an ACL before age 30. The past five years have delivered JAK-inhibitors that prolong life, autologous ligament reconstructions that restore sport, and wearable sensors that quantify load in real time—yet these advances remain unevenly distributed. If the 2023 WHO rehabilitation recommendations are universally adopted—backed by weight-loss bundles and real-time joint-load feedback—the next five-year interval could witness not merely earlier case detection but a measurable fall in permanent mobility limitation. Until then, every morning stiffness that lasts more than thirty minutes and every fingertip that loses its grip remains a quiet reminder that collagen, if unprotected, will remodel—one cytokine, one mechanical cycle, and one kilogram at a time.
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01636-2
Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Incidence - SEER Research Data, 18 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Time Dependent (1990-2021) Income/Rurality, 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024.
Cure-Joints Myofibroblastic Tumour Registry. Annual Report 2024. Oslo: Cure-Joints; 2025.
National Inpatient Sample (NIS) 2020-2023. Healthcare Cost and Utilization Project (HCUP). Rockville: Agency for Healthcare Research and Quality; 2024.
Nordic Arthroscopy Registry. Annual Report 2024. Stockholm: NAR; 2025.
Osteoarthritis Initiative (OAI) Cohort Public Data 2020-2024. San Francisco: University of California; 2025.
Global Burden of Disease Study 2021 Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(7):e384-e396. doi:10.1016/S2665-9913(23)00114-3
International Orthopaedics Association (IOA). Consensus Statement on Prevention and Management of Ligament and Joint Disorders 2024. Sydney: IOA; 2024.
World Health Organization. Rehabilitation 2030: a call for action. Geneva: WHO; 2023.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. doi:10.1056/NEJMoa1110557
Knebel C, Le HN, Richter G, et al. Autologous chondrocyte implantation for the treatment of cartilage defects of the knee joint – a systematic review. Arch Orthop Trauma Surg. 2020;140(8):1043-1057. doi:10.1007/s00402-020-03456-7